Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23469718 | 1.00 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL30140726 | 1.00 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL30140735 | 0.91 | KLKB1 (0.83) | KLKB1BTK | |
| SCHEMBL23469719 | 0.91 | KLKB1 (0.83) | KLKB1BTK | |
| SCHEMBL23469516 | 0.91 | KLKB1 (0.83) | KLKB1BTK | |
| SCHEMBL23469534 | 0.90 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL20540794 | 0.90 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL30140706 | 0.90 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL23469709 | 0.89 | KLKB1 (1.00) | KLKB1BTK | |
| SCHEMBL23469509 | 0.89 | KLKB1 (1.00) | KLKB1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| US-20180305339-A1 | Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305339-A1 | Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885BTK 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.